Randomized Controlled Trials for the Treatment of Hidradenitis Suppurativa

Dermatol Clin. 2016 Jan;34(1):69-80. doi: 10.1016/j.det.2015.08.012.

Abstract

Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease. Several treatment modalities are available, but most of them lack high-quality evidence. A systematic search was performed to identify all randomized controlled trials for the treatment of HS in order to review and evaluate the evidence. Recommendations for future randomized controlled trials include using validated scores, inclusion of patient rated outcomes, and thorough report of side effects. Evidence for long-term treatment and benefit/risk ratio of available treatment modalities is needed in order to enhance evidence-based treatment in daily clinical practice. Combining surgery with antiinflammatory treatment warrants further investigation.

Keywords: Antibiotics; Biologics; Evidence based; Hidradenitis suppurativa; Laser; Randomized controlled trials; Surgery; Treatment.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Dermatologic Agents / therapeutic use
  • Dermatologic Surgical Procedures / methods
  • Ethinyl Estradiol-Norgestrel Combination / therapeutic use
  • Hidradenitis Suppurativa / therapy*
  • Hormones / therapeutic use
  • Humans
  • Infliximab / therapeutic use
  • Intense Pulsed Light Therapy / methods
  • Laser Therapy / methods
  • Low-Level Light Therapy / methods
  • Outcome Assessment, Health Care
  • Randomized Controlled Trials as Topic

Substances

  • Anti-Bacterial Agents
  • Dermatologic Agents
  • Hormones
  • Ethinyl Estradiol-Norgestrel Combination
  • Infliximab